Acamprosate for Alcoholism

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Alcoholism+1 More
Acamprosate - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new way to help people with Alcohol Use Disorder (AUD), by trying to find biomarkers that show if a person will respond to a medication called acamprosate.

Eligible Conditions
  • Alcoholism
  • Alcohol Use Disorder

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

0 Primary · 1 Secondary · Reporting Duration: The number of days until first alcohol use assessed by TLFB during 3 months of treatment

Month 3
Alcohol Timeline Follow Back

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Acamprosate
1 of 2
Placebo
1 of 2

Active Control

Non-Treatment Group

800 Total Participants · 2 Treatment Groups

Primary Treatment: Acamprosate · Has Placebo Group · Phase 4

Acamprosate
Drug
ActiveComparator Group · 1 Intervention: Acamprosate · Intervention Types: Drug
Placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: the number of days until first alcohol use assessed by tlfb during 3 months of treatment

Who is running the clinical trial?

National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
711 Previous Clinical Trials
1,170,091 Total Patients Enrolled
371 Trials studying Alcoholism
972,886 Patients Enrolled for Alcoholism
Mayo ClinicLead Sponsor
2,893 Previous Clinical Trials
3,697,897 Total Patients Enrolled
7 Trials studying Alcoholism
1,158 Patients Enrolled for Alcoholism
Victor M KarpyakPrincipal InvestigatorMayo Clinic
Victor M Karpyak, MD, Ph.D.Principal InvestigatorMayo Clinic

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are able to provide informed consent.
You are willing to use the study medications for 3 months and attend follow-up visits.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 4th, 2021

Last Reviewed: November 3rd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.